Edition:
United States

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.55CAD
4:00pm EDT
Change (% chg)

$0.06 (+12.24%)
Prev Close
$0.49
Open
$0.52
Day's High
$0.59
Day's Low
$0.52
Volume
2,005,425
Avg. Vol
1,509,901
52-wk High
$1.80
52-wk Low
$0.43

Latest Key Developments (Source: Significant Developments)

Prometic Life Sciences Q4 Total Revenue $6.6 Mln Vs $4.1 Mln
Wednesday, 28 Mar 2018 08:59pm EDT 

March 28 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS Q4-2017 AND YE-2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON ACTIVITIES.‍TOTAL REVENUES FOR Q4 ENDED DECEMBER 31, 2017 WERE $6.6 MILLION COMPARED TO $4.1 MILLION FOR Q4 ENDED DECEMBER 31, 2016​.PROMETIC LIFE SCIENCES - ‍RECEIVED FDA INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO COMMENCE ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF PBI-4050 DRUG ​.  Full Article

Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins
Monday, 5 Mar 2018 07:00am EST 

March 5 (Reuters) - Prometic Life Sciences Inc ::PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS.PROMETIC LIFE SCIENCES INC - ‍COSTS ASSOCIATED WITH CLINICAL PROGRAM WILL NOT IMPACT FY2018​.  Full Article

Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins
Monday, 5 Mar 2018 07:00am EST 

March 5 (Reuters) - Prometic Life Sciences Inc ::PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS.PROMETIC LIFE SCIENCES INC - IN ADDITION TO RARE PEDIATRIC DISEASE DESIGNATION, IAIP HAS ALSO BEEN GRANTED AN ORPHAN DRUG DESIGNATION BY FDA.PROMETIC LIFE SCIENCES - COSTS ASSOCIATED WITH CLINICAL PROGRAM RELATED TO THE PEDIATRIC & ORPHAN DRUG DESIGNATIONS "WILL NOT IMPACT OUR FY2018.  Full Article

Prometic Granted Orphan Drug Designation By FDA
Thursday, 15 Feb 2018 08:41am EST 

Feb 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR INTER-ALPHA-INHIBITOR-PROTEINS FOR TREATMENT OF NECROTIZING ENTEROCOLITIS (NEC).PROMETIC LIFE SCIENCES INC - ORPHAN DRUG DESIGNATION STATUS HAS BEEN GRANTED TO ITS IAIP FOR TREATMENT OF NECROTIZING ENTEROCOLITIS BY U.S. FDA.  Full Article

Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized
Monday, 29 Jan 2018 06:30am EST 

Jan 29 (Reuters) - Prometic Life Sciences Inc ::PROMETIC'S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED.PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN "ALL COMERS STUDY".PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT.  Full Article

Prometic reports positive interim clinical data from IVIG phase 3 trial
Wednesday, 22 Nov 2017 07:00am EST 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​.  Full Article

Prometic Q3 revenue C$24 million versus C$3.7 million
Monday, 13 Nov 2017 08:24pm EST 

Nov 13 (Reuters) - Prometic Life Sciences Inc :Prometic reports 2017 third quarter highlights and financial results.Q3 revenue C$24 million versus C$3.7 million.Q3 revenue view c$6.9 million -- Thomson Reuters I/B/E/S.Prometic Life Sciences - ‍incurred a net loss of $17.8 million for quarter ended sept 30, compared to net loss of $28.0 million for quarter ended Sept 30, 2016​.  Full Article

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Prometic Life Sciences Inc ::Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation.Prometic Life Sciences Inc - ‍up to 33 adult patients are expected to be enrolled in clinical trial​.  Full Article

Prometic enters LOI for $80 mln line of credit from Structured Alpha LP
Monday, 23 Oct 2017 05:30am EDT 

Oct 23 (Reuters) - Prometic Life Sciences Inc ::Prometic enters into binding letter of intent to secure usd $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.Company to grant Structured Alpha LP an initial 10 million warrants with an exercise price of CAD $1.70 per common share​.Company to also grant Structured Alpha LP additional 44 million warrants at exercise price of CAD $1.70 per common share​.  Full Article

FDA accepts Prometic's Biologics License Application for Plasminogen
Friday, 13 Oct 2017 06:30am EDT 

Oct 13 (Reuters) - Prometic Life Sciences Inc :Prometic announces FDA acceptance of its Biologics License Application for Plasminogen (Ryplazim™).Prometic Life Sciences Inc - ‍prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018​.  Full Article